Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Hansoh BioMedical R&D Company: Clinical Trials & FDA Approval Profile

Hansoh BioMedical R&D Company (Global / Institutional) sponsors 26 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 16 active protocols (9 recruiting now), 2 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)3.9%
Median Closed Enrollment vs National (145 pts)292 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Hansoh BioMedical R&D Company
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)26
Active Pipeline (Recruiting Now)16 (9)
Completed vs Stopped Early2 / 1 (3.9%)
Median Closed Actual Enrollment292 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Hansoh BioMedical R&D Company
Hospital Research SiteLocationShared Protocols
Henan Cancer HospitalZhengzhou, Henan5
Harbin Medical University Cancer HospitalHarbin, Heilongjiang5
Zhejiang Cancer HospitalHangzhou, Zhejiang4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Hansoh BioMedical R&D Company
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06112704HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid TumorsPhase IIRECRUITING
NCT05830123ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasPhase IIRECRUITING
NCT06007729ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid TumorsPhase IIRECRUITING
NCT06014190HS-20089 in Patients With Ovarian Cancer and Endometrial CancerPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Hansoh BioMedical R&D Company Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI